TL;DR
- 1.GH peptide receptors (GHS-R1a) recover in roughly 6 hours after a single acute dose. After weeks of daily dosing, full receptor re-expression takes 21-28 days.
- 2.Hexarelin desensitizes fastest: 40-50% response drop by day 14. GHRP-2 and ipamorelin are far more forgiving and often maintain 85%+ response across a 10-week cycle.
- 3.MK-677 shows minimal receptor desensitization in human trials. Clinical crossover studies used only 14-21 day washout periods and found near-complete receptor rebound.
- 4.Pulsed dosing (5 days on, 2 days off per week) preserves receptor sensitivity better than continuous daily use and may eliminate the need for hard macro-cycle breaks.
- 5.Your GHS-R1a genetics change how fast you desensitize and how quickly you bounce back. Standard 4-week breaks work for most people, not all.
Your GH peptide receptors can fully recover in 6 hours. In a test tube. In your body, run ipamorelin daily for 10 weeks and that same recovery takes 21-28 days. The catch: most cycling protocols in circulation were built around a number nobody actually measured in humans. It spread from forums, not from a study.
GHS-R1a receptor recovery after a single acute dose: approximately 6 hours in vitro. Recovery after chronic 10-week daily dosing: 21-28 days in vivo. Same receptor. Completely different biology.
The standard "8 weeks on, 4 weeks off" recommendation is practitioner convention, not a trial-derived number. It is a reasonable guess built on receptor biology theory, but theory and measured outcome are not the same thing. The actual receptor science tells a more precise story. And it varies depending on which peptide you ran, how long you ran it, and your underlying GHS-R1a genetics.
Here is what the research actually shows, week by week.
Think of your GHS-R1a receptor like a doorbell button. Ring it once and it springs back immediately. Ring it 50 times a day for 10 weeks and the spring mechanism inside starts to stick. Two things happen: the button gets pulled inside the wall where you cannot press it (internalization), and the mechanism that is supposed to return it to the surface slows down under chronic load. The 4-week off-period is time for that spring to reset. How long it actually takes depends entirely on how hard you pushed it.
Why Your GH Peptide Receptors Stop Responding in the First Place
GH secretagogue peptides (ipamorelin, CJC-1295, GHRP-2, GHRP-6, hexarelin) work by binding to GHS-R1a receptors on the pituitary gland. Each binding event triggers a GH pulse. That part is well understood. What happens next is where most cycling guides go wrong.
When GHS-R1a is activated repeatedly over days and weeks, two parallel processes accelerate. First, the activated receptor gets pulled from the cell surface into the interior of the cell (receptor internalization). Second, the slow endosomal recycling pathway that normally returns the receptor to the surface becomes overwhelmed. A 2014 review published in Vitamins and Hormones described this specifically: GHS-R1a accumulates in perinuclear endosomes during sustained activation, where it remains bound to ligand and is largely unavailable for re-signaling. The receptor is not destroyed. It is stuck in a traffic jam inside the cell.
This is classical receptor desensitization, and it explains why people running long uninterrupted GH peptide cycles often report that the pulse effect disappears by week 8 or 10 even at the same dose. The receptor count at the cell surface has dropped. The signal is still being sent. Fewer addresses are receiving it.
A 2004 analysis of GHS-R1a internalization mechanics published in Peptides confirmed that surface receptor recovery following acute single-dose activation was rapid (near-complete within several hours in vitro). The problem is that chronic activation does not produce a simple amplification of that acute response. The recycling machinery is trained by frequency and duration. High-frequency chronic stimulation, like daily peptide injections across 10 weeks, forces receptor internalization rates that outpace the recycling pathway's capacity, leading to a net reduction in surface receptor density over time.
Which GH Peptides Desensitize Fastest (And Which Are Far More Forgiving)
Not all GH secretagogues affect receptor internalization equally. This is the detail most cycling guides get wrong by treating the entire class as interchangeable. The differences are significant enough to completely change your off-period calculation.
Research published in the Journal of Endocrinology in 2004 found that hexarelin drove rapid GHS-R1a desensitization in vitro, with 40-50% response reduction observable at high concentrations within 14 days of sustained exposure. Hexarelin's high receptor affinity, while responsible for its potent acute GH response, also drives aggressive internalization. If you ran hexarelin, a minimum 5-6 week off-period is appropriate before restarting.
Among the GHRP class, GHRP-2 shows the lowest desensitization profile. Protocol literature and receptor kinetics data suggest GHRP-2 maintains approximately 85-90% of initial GH response across 10-12 week cycles at standard doses. The practical implication: a standard 3-4 week off-period is adequate for most GHRP-2 users, and some protocols extend continuous use to 16 weeks without significant response blunting.
Ipamorelin is selective for the GH pulse without triggering cortisol or prolactin spikes, which makes it the most common clinical choice. Its receptor desensitization profile sits between GHRP-2 and hexarelin. After a standard 8-10 week cycle, a 4-6 week off-period restores roughly 70-85% of initial GH pulse amplitude. The 4-week minimum works for most users; 5-6 weeks is appropriate after longer or higher-dose cycles.
MK-677 is an orally active ghrelin mimetic, not an injected peptide, and its receptor interaction profile differs meaningfully. Human trials using MK-677 at 25 mg daily for up to 12 months showed minimal receptor desensitization compared to injected GHRPs. Clinical crossover studies used 14-21 day washout periods and found near-complete receptor rebound. The continuous low-level receptor engagement from oral bioavailability appears to produce less aggressive internalization than pulsed high-concentration injections.
"Rapid desensitisation of the GH secretagogue receptor to hexarelin was observed in vitro, confirming that agonist concentration and duration of exposure are primary determinants of receptor internalization rate and that GHS-R1a desensitization is ligand-selective rather than a class-wide phenomenon."
Journal of Endocrinology, 2004
The practical takeaway: your off-period should match your peptide's receptor kinetics, not a blanket number from a forum post. Hexarelin users and ipamorelin users need different recovery windows.
The GH Receptor Reset Timeline: What Each Week Actually Looks Like
There is no large-scale human clinical trial that measured GHS-R1a surface receptor density week by week during a peptide off-cycle. The numbers below are derived from in vitro receptor kinetics data, animal model washout studies, and clinical protocol literature on GH axis recovery timelines. They represent the best available estimate, not a confirmed human measurement. That caveat matters and you should hold these ranges accordingly.
| Off-Cycle Week | Estimated Receptor Recovery | What You May Notice |
|---|---|---|
| Week 1 | 20-30% | Sleep quality may shift as the artificially elevated GH pulse pattern clears. IGF-1 begins declining from cycle peak. Some users report temporary fatigue as the GH axis resets its natural rhythm. |
| Week 2 | 40-55% | GH pulsatility begins restoring toward natural pattern. Some users notice improved deep sleep quality as the pituitary reestablishes its nocturnal GH release rhythm without external stimulation. |
| Week 3 | 60-75% | Most of the accessible recovery has occurred. This is where GHRP-2 users can often restart effectively. Ipamorelin users may still benefit from an additional week. |
| Week 4 | 75-85% | The standard "4-week off" endpoint. Adequate for most ipamorelin and GHRP-2 protocols at standard doses. Not enough for hexarelin or for extended high-dose cycles of any peptide. |
| Weeks 5-6 | 85-95% | Recommended recovery window for hexarelin users and for anyone who ran a 12+ week cycle at higher doses. Also appropriate for anyone restarting after two consecutive macro-cycles with minimal off-time. |
| Weeks 7-8 | Near complete | Full receptor re-expression for most users. Beneficial for those with GHS-R1a variants that slow receptor recycling, or for anyone who had a suboptimal response on prior restart attempts at the 4-week mark. |
One number worth remembering: 21-28 days is the minimum for meaningful receptor re-expression after chronic use. This means the popular "3-week break" leaves most users at roughly 55-65% receptor recovery before they restart. They will see some response. They will not see what they saw in week one of their first cycle.
How to Know Your Receptors Have Actually Reset (Not Just Assumed)
Most people restart their cycle after a fixed number of calendar weeks and hope the receptor is ready. There is a better approach, and it does not require guessing.
IGF-1 testing is your proxy for receptor recovery. During an active GH peptide cycle, IGF-1 typically rises 20-40% above your personal baseline. When you stop, it declines. When IGF-1 returns to your pre-cycle baseline on a blood draw, that is the most reliable signal that the GH axis has normalized and receptor sensitivity has likely restored. If your IGF-1 is still elevated three weeks into your break, your GH axis has not finished resetting. Wait and retest before restarting.
IGF-1 testing is not expensive. LabCorp and Quest both offer standalone IGF-1 panels for under $60 out of pocket. A single draw at weeks 3-4 of your off-period tells you more than a calendar can.
The second signal is response quality on restart. When receptors have properly reset, your first dose of ipamorelin or GHRP-2 after the off-period should produce a noticeable effect: improved sleep depth that night, mild skin warmth, increased appetite. These are the signs of a real GH pulse. If you restart and feel nothing, either the receptors are not fully recovered or the dose needs recalibration. Do not assume the peptide is faulty. Assume the reset was incomplete.
The minimum off-period for meaningful GHS-R1a receptor re-expression after chronic GH peptide use. The widely used "4-week break" sits at the bottom of this window, not the middle. It works for most users on standard protocols, but it is not a cushion.
Why Your GH Receptor Genetics Change the Entire Equation
Two people can run identical ipamorelin protocols for 10 weeks and come off cycle with completely different receptor states. Some of that difference is dose and lifestyle. A meaningful portion is genetic.
The GHSR gene codes for the GH secretagogue receptor. Well-documented variants in this gene affect baseline receptor density, receptor affinity, and the rate at which the receptor internalizes under stimulation. People who carry variants associated with lower receptor density desensitize faster under the same stimulation and need a longer off-period to restore sensitivity. People with higher-density or higher-affinity variants may get more response per cycle and recover faster during the off-period.
There is also a GH receptor gene (GHR) variant related to the Leu378 polymorphism that reduces downstream GH signaling even when GHS-R1a receptor sensitivity is fully intact. If you follow a textbook protocol, take a textbook recovery period, and still see a weaker response on restart than you expected, this variant is a logical suspect. It means the problem is downstream of the receptor, not at the receptor itself. Our DNA-first peptide decision framework walks through how to assess whether your GH axis genetics favor secretagogue approaches at all before you commit to a cycle.
Your CYP enzyme profile also matters here. Slow CYP3A4 metabolizers clear long-acting analogs like CJC-1295 more slowly than standard pharmacokinetics predict. If you clear the peptide slowly, the effective receptor stimulation window from each dose extends beyond what the nominal half-life implies. That means you are accumulating more receptor stimulation per week than a standard dosing schedule suggests, and your off-period may need to be proportionally longer than the baseline recommendation.
You can get your GHSR and CYP enzyme profile from any 23andMe, AncestryDNA, or MyHeritage dataset. Our full peptide report includes these variants in the context of your complete GH axis response profile.
Cycling Protocols That Actually Preserve Receptor Sensitivity Over Time
The goal during the on-cycle is not only to maximize each GH pulse. It is to preserve enough receptor surface density that each pulse still produces a measurable response at week 10. These protocols accomplish that without requiring you to sacrifice the entire benefit period.
| Protocol | On-Cycle Duration | Off-Cycle Duration | Best For |
|---|---|---|---|
| Standard macro-cycle | 8-10 weeks daily | 4-6 weeks | Ipamorelin, GHRP-2; most users; first-cycle baseline |
| Extended macro-cycle | 12-16 weeks daily | 6-8 weeks | GHRP-2 only; hexarelin users need 8 weeks off regardless of cycle length |
| Weekly micro-cycle | 5 days on, 2 days off per week, indefinitely | No hard macro-cycle break required; add a 3-week break every 16-20 weeks for full axis normalization | Ipamorelin, GHRP-2; long-term users who prefer continuous benefit without quarterly breaks |
| CJC-1295 with DAC | 8-12 weeks (one injection per week) | 6-8 weeks minimum (DAC half-life of 6-8 days requires longer washout) | CJC-1295 with DAC only; the extended half-life means receptor stimulation continues for days after each injection |
| MK-677 long run | 3-6 months continuous at 10-25 mg daily | 3-4 weeks minimum; some clinical protocols use 2-3 week washouts for crossover studies | MK-677 only; supported by human trial data showing minimal desensitization at standard doses over 12-month periods |
The weekly micro-cycle deserves more attention than it gets. Receptor internalization research shows that two consecutive days without GHS-R1a activation are sufficient for partial resensitization in most receptor variants. Running 5 days on and 2 days off effectively resets a portion of the internalized receptor pool each week, which dramatically extends the useful life of an on-period. Many long-term ipamorelin users report more consistent results across a 16-week micro-cycle than across two separate 8-week macro-cycles with 4-week breaks between them.
What the 2026 Regulatory Reclassification Actually Changes
In February 2026, HHS announced that approximately 14 peptides, including CJC-1295 and ipamorelin, would be reclassified from FDA Category 2 (restricted from pharmacy compounding) back to Category 1 status. This change, effective April 23, 2026, reopened the pathway for licensed 503A compounding pharmacies to prepare these compounds under a valid physician prescription.
The practical impact on your protocol: pharmaceutical-grade compounded peptides from a licensed pharmacy reduce the batch-to-batch concentration variance that is common with gray-market sources. Concentration variance in your peptide supply is a silent variable that makes cycle length and recovery period calculations unreliable. A vial labeled 5 mg that contains 3.8 mg or 6.1 mg changes your effective dose significantly, which in turn changes your receptor desensitization rate. Sourcing from a licensed compounding pharmacy removes that variable.
For a full breakdown of the 2026 legal landscape and what the Category 1 reclassification means in practice, see our 2026 peptide legality guide.
For a detailed side-by-side comparison of how CJC-1295 and ipamorelin differ on receptor kinetics and pulse quality, see the ipamorelin vs CJC-1295 deep dive. And for the complete framework on how to structure peptide cycles across all classes (not just GH secretagogues), the peptide cycling protocol guide covers the full picture.
If you want to know whether GH secretagogues are the right category for your biology before committing to a 10-week cycle, a personalized ipamorelin profile from your genetic data identifies your GHS-R1a variant, your CYP clearance profile, and your downstream GH signaling genetics in a single report.
Your DNA shapes how you respond to the peptides discussed above.
A personalized report scores 25+ peptides against your unique genetic profile — including the ones covered in this article.
Frequently asked questions
How long should I stay off GH peptides before starting a new cycle?
The minimum is 3-4 weeks for ipamorelin and GHRP-2, 5-6 weeks for hexarelin, and 2-3 weeks for MK-677. The most reliable signal to restart is when your IGF-1 returns to your pre-cycle baseline on a blood test. Calendar-based rules work for most people but miss individual variation in receptor recovery speed, especially if you have GHSR genetic variants that slow recycling.
Do GH peptide receptors really desensitize that fast?
It depends heavily on the peptide. Hexarelin can reduce receptor response 40-50% within 14 days at sustained concentrations, making it the fastest-desensitizing compound in the class. Ipamorelin and GHRP-2 are much more forgiving, often maintaining significant sensitivity across 10-12 week cycles when dosed correctly. MK-677 shows the least desensitization in human trials, which is why some people run it for 3-6 months without a full break.
What is the 5 days on, 2 days off protocol and does it actually work?
The weekly micro-cycle gives GHS-R1a receptors two recovery days per week, which allows partial resensitization before the next five-day on-period begins. Research on receptor internalization shows that even brief ligand-free periods allow a portion of internalized receptors to recycle back to the cell surface. Many long-term ipamorelin users report more consistent results on 5-on/2-off than on continuous daily dosing followed by quarterly breaks.
How do I know when my GH receptors have actually reset?
The most objective signal is your IGF-1 returning to your personal pre-cycle baseline on a blood test. You can get IGF-1 tested for under $60 at LabCorp or Quest without a doctor's order in most states. Subjectively, your first dose after a proper reset should produce noticeable effects: improved sleep depth that night, mild skin warmth, and increased appetite. If you restart and feel nothing, the off-period may have been too short.
Does genetics affect how quickly GH receptors reset?
Yes, meaningfully. GHSR gene variants affect baseline receptor density, which changes how quickly you desensitize and how long recovery takes. People with lower receptor density variants may need 5-7 weeks off after the same cycle that a standard-density carrier can recover from in 4 weeks. A DNA report that includes GHSR and GH receptor variants gives you a much more accurate off-period target than any population-level recommendation.
Can I run ipamorelin indefinitely on a micro-cycle without a full break?
Most clinical protocol frameworks still recommend a full 3-4 week break every 16-20 weeks even on a 5-on/2-off micro-cycle, to allow complete GH axis normalization beyond just receptor recycling. The weekly micro-cycle preserves receptor sensitivity well, but a periodic full break lets your natural pulsatile GH release pattern reset and helps prevent any gradual drift in IGF-1 that can accumulate over months of continuous stimulation.
Does CJC-1295 with DAC need a longer off-period than CJC-1295 without DAC?
Yes. CJC-1295 with the Drug Affinity Complex (DAC) has a half-life of approximately 6-8 days compared to roughly 30 minutes for the no-DAC version. After your last weekly injection, the peptide continues to stimulate receptors for another 2-3 weeks as it clears. This effectively extends your on-cycle and means your off-period needs to account for that tail. A 6-8 week off-period is appropriate after a CJC-1295 DAC cycle, compared to 4-5 weeks for no-DAC protocols.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary.